Niora J. Fabian

Niora J. Fabian

Auto-generated profile, based on publicly available information

Niora J. Fabian

Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
BYBinbin Ying
Binbin Ying
KNKewang Nan
Kewang Nan
QZQing Zhu
Qing Zhu
TKTom Khuu
Tom Khuu
HRHana Ro
Hana Ro
GTGiovanni Traverso
Giovanni Traverso
Establishing a robust and intimate mucosal interface that allows medical devices to remain within lumen-confined organs for extended periods has valuable applications, particularly for gastrointestinal theranostics. Here, we report the development of an electroadhesive hydrogel interface for robust and prolonged mucosal retention after electrical activation (e-GLUE). The e-GLUE device is composed of cationic polymers interpenetrated within a tough hydrogel matrix. An e-GLUE electrode design eliminated the need for invasive submucosal placement of ground electrodes for electrical stimulation during endoscopic delivery. With an electrical stimulation treatment of about 1 minute, the cationic polymers diffuse and interact with polyanionic proteins that have a relatively slow cellular turnover rate in the deep mucosal tissue. This mucosal adhesion mechanism increased the adhesion energy of hydrogels on the mucosa by up to 30-fold and enabled in vivo gastric retention of e-GLUE devices in a pig stomach for up to 30 days. The adhesion strength was modulated by polycationic chain length, electrical stimulation time, gel thickness, cross-linking density, voltage amplitude, polycation concentration, and perimeter-to-area ratio of the electrode assembly. In porcine studies, e-GLUE demonstrated rapid mucosal adhesion in the presence of luminal fluid and mucus exposure. In proof-of-concept studies, we demonstrated e-GLUE applications for mucosal hemostasis, sustained local delivery of therapeutics, and intimate biosensing in the gastrointestinal tract, which is an ongoing clinical challenge for commercially available alternatives, such as endoclips and mucoadhesive. The e-GLUE platform could enable theranostic applications across a range of digestive diseases, including recurrent gastrointestinal bleeding and inflammatory bowel disease.

22 December 2023 in Science Advances
Verified
Journal Article
Open access
HHHugh Herr
Hugh Herr
AAAmro Alshareef
Amro Alshareef
AHAlexandria Hwang
Alexandria Hwang
CBCeara Byrne
Ceara Byrne
JKJohannes Kuosmanen
Johannes Kuosmanen
GTGiovanni Traverso
Giovanni Traverso
Effective therapies for obesity require invasive surgical and endoscopic interventions or high patient adherence, making it challenging for patients with obesity to effectively manage their disease. Gastric mechanoreceptors sense distension of the stomach and perform volume-dependent vagal signaling to initiate the gastric phase and influence satiety. In this study, we developed a new luminal stimulation modality to specifically activate these gastric stretch receptors to elicit a vagal afferent response commensurate with mechanical distension. We designed the Vibrating Ingestible BioElectronic Stimulator (VIBES) pill, an ingestible device that performs luminal vibratory stimulation to activate mechanoreceptors and stroke mucosal receptors, which induces serotonin release and yields a hormonal metabolic response commensurate with a fed state. We evaluated VIBES across 108 meals in swine which consistently led to diminished food intake (~40%,P< 0.0001) and minimized the weight gain rate (P< 0.05) as compared to untreated controls. Application of mechanoreceptor biology could transform our capacity to help patients suffering from nutritional disorders.

1 January 2020 in Veterinary Microbiology
Verified
Journal Article
Closed access
NFNiora J. Fabian
Niora J. Fabian
AMAnthony J. Mannion
Anthony J. Mannion
YFYan Feng
Yan Feng
CMCarolyn M. Madden
Carolyn M. Madden
JFJames G. Fox
James G. Fox

1 September 2021 in Journal of the American Association for Laboratory Animal Science
Verified
Journal Article
Closed access
NFNiora J Fabian
Niora J Fabian
DMDavid E Moody
David E Moody
OAOlga Averin
Olga Averin
WFWenfang B Fang
Wenfang B Fang
MJMorgan Jamiel
Morgan Jamiel
JHJennifer L Haupt
Jennifer L Haupt
Although buprenorphine is the most frequently used opioid analgesic in common marmosets (Callithrix jacchus), there is limited information in the literature supporting current dosing regimens used for this species. The purpose of this study was to determine the pharmacokinetic profiles of single-dose buprenorphine HCl administered intramuscularly (IM) at 0.01 mg/kg in 6 adult marmosets (1.8 to 12.8 y old; 2 males, 4 females) and subcutaneously (SQ) at 0.01 mg/kg in 6 adult marmo- sets (2.3-4.4 y old; 3 males, 3 females) by mass spectrometry. Blood was collected at multiple time points from 0.25 to 24 h from unsedated animals following a hybrid sparse-serial sampling design. The maximal observed plasma concentration of buprenorphine (Cmax) administered IM (2.57 ± 0.95 ng/mL) was significantly higher than administered SQ (1.47 ± 0.61 ng/mL). However, the time to Cmax(Tmax) was not statistically different between routes (17.4 ± 6 min for IM and 19.8 ± 7.8 min for SQ). The time of the last quantifiable concentration of buprenorphine was 5 ± 1.67 h for IM compared with 6.33 ± 1.51 h for SQ, which was not statistically different. The mean buprenorphine plasma concentration-time curves were used to propose a dosing frequency of 4 to 6 h for buprenorphine at 0.01 mg/kg IM or SQ based on a theoretical therapeutic plasma concentration threshold of 0.1 ng/mL. Based on the mean pharmacokinetic parameters and plasma-concentration time curves, both IM and SQ routes of buprenorphine at this dose provide a rapid increase in the plasma concentration of buprenorphine above the therapeutic threshold, and may be more effective for acute rather than long-lasting analgesia. Further studies are needed to examine repeated dosing regimens and the efficacy of buprenorphine in common marmosets.

22 October 2025 in Science Robotics
Verified
Journal Article
Closed access
JCJ. Chen
J. Chen
AAA. Alexiev
A. Alexiev
ASA. Sergnese
A. Sergnese
NFN. Fabian
N. Fabian
APA. Pettinari
A. Pettinari
GTG. Traverso
G. Traverso
Acute mesenteric ischemia (AMI) results from insufficient blood flow to the intestines, leading to tissue necrosis with high morbidity and mortality. Diagnosis is often delayed because of nonspecific symptoms that mimic common gastrointestinal conditions. Current diagnostic methods, such as computed tomography and mesenteric angiography, are complex, costly, and invasive, highlighting the need for a rapid, accessible, and minimally invasive alternative. Here, we present FIREFLI (finding ischemia via reflectance of light), a bioinspired, ingestible capsule designed for luminance-based diagnosis of AMI. Upon ingestion, the device activates in the small intestine’s pH environment, emitting pulses from three radially spaced white light-emitting diodes and measuring reflected light across 10 wavelengths. FIREFLI then computes a tissue luminance biomarker, which outperforms color-change biomarkers because of superior intrasubject consistency. The diagnosis is processed onboard and wirelessly transmitted to an external mobile device. In vivo studies in swine ( n = 9) demonstrated a diagnostic accuracy of 90%, with a sensitivity of 98% and specificity of 85%. By providing a noninvasive, real-time diagnostic solution, FIREFLI has the potential to facilitate earlier detection and treatment of AMI, ultimately improving patient outcomes.

22 July 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NFNiora J. Fabian
Niora J. Fabian
AMAnthony J. Mannion
Anthony J. Mannion
MJMorgan Jamiel
Morgan Jamiel
DADavid. J. Anderson
David. J. Anderson
JRJoseph E. Rower
Joseph E. Rower
JHJennifer L. Haupt
Jennifer L. Haupt
While sustained-release buprenorphine (BSR) is used as a long-lasting opioid analgesic in common marmosets (Callithrix jacchus), there are no published studies on pharmaceutical-grade extended-release buprenorphine options such as Ethiqa XR (EXR) for this species. However, BSR is a compounded product and has been reported to cause injection site reactions in multiple species, including marmosets. Additionally, now with the availability of EXR, a pharmaceutical-grade veterinary product, the use of BSR in laboratory animals is not compliant with the Guide for the Care and Use of Laboratory Animals (Guide) unless scientifically justified and approved by the IACUC. We compared pharmacokinetic and safety profiles of BSR (0.15 mg/kg) and EXR (0.1–0.2 mg/kg) administered subcutaneously to adult marmosets. Blood was collected by venipuncture of the saphenous vein at multiple time points (0.25–72 h) and analyzed by liquid chromatography-tandem mass spectrometry (LC–MS/MS). EXR between 0.1 and 0.2 mg/kg resulted in a dose-dependent increase in Cmax (1.43–2.51 ng/mL) and were not statistically different from BSR (1.82 ng/mL). Tmax, lambdaz, and t1/2 were not statistically different between formulations. Mean plasma buprenorphine concentrations for BSR and EXR exceeded the therapeutic threshold (0.1 ng/mL) within 0.25 h and lasted for > 72 h. Mild sedation, but neither respiratory depression nor ataxia, was observed for both formulations. BSR injection sites had significantly higher histopathological scores compared to EXR. Video recordings for monitoring drug-induced behavioral changes showed increased animal activity levels after BSR and EXR versus saline controls. Norbuprenorphine, a buprenorphine metabolite associated with respiratory depression, was detected in the plasma after BSR and EXR administration as well as by in vitro liver microsome assays. In conclusion, we recommend using EXR over BSR as a long-lasting buprenorphine analgesic in marmosets because EXR is a pharmaceutical-grade formulation that is compliant with FDA guidelines and the Guide as well as exhibits comparable PK and safety profiles as BSR.